Initial Testing (Stage 1) of the PARP Inhibitor BMN 673 by the Pediatric Preclinical Testing Program: PALB2 Mutation Predicts Exceptional in Vivo Response to BMN 673

INTRODUCTION: BMN 673 is a potent inhibitor of poly-ADP ribose polymerase (PARP) that is in clinical testing with a primary focus on BRCA-mutated cancers. BMN 673 is active both through inhibiting PARP catalytic activity and by tightly trapping PARP to DNA at sites of single strand breaks. METHODS:...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Pediatr Blood Cancer
Autors principals: Smith, Malcolm A., Hampton, Oliver A., Reynolds, C. Patrick, Kang, Min H., Maris, John M., Gorlick, Richard, Kolb, E. Anders, Lock, Richard, Carol, Hernan, Keir, Stephen T., Wu, Jianrong, Kurmasheva, Raushan T., Wheeler, David A., Houghton, Peter J.
Format: Artigo
Idioma:Inglês
Publicat: 2014
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4456187/
https://ncbi.nlm.nih.gov/pubmed/25263539
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pbc.25201
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars